chPD1

**chPD1** is a chimeric switch receptor engineered into autologous T lymphocytes, fusing the extracellular ligand-binding domain of programmed cell death protein 1 (**PD-1**) with the transmembrane and cytoplasmic co-stimulatory signaling domains of **CD28** (and sometimes **Dap10** and **CD3zeta**). This modification converts the inhibitory **PD-1/PD-L1** interaction into a stimulatory signal, preventing T-cell suppression by **PD-L1**-expressing tumor cells and instead promoting T-cell activation, proliferation, cytokine production, and enhanced cytotoxicity against tumors. Developed for adoptive cell therapy, it shows potent antitumor activity in preclinical models of solid tumors (e.g., pancreatic cancer, lymphoma) and gamma-delta T cells, with plans for Phase I/II clinical trials, particularly sensitizing tumors resistant to standard **PD-1** inhibitors.[2][3][5][7][8][9][14]

Other names

chPD1chPD-1chPD 1chimeric PD1PD1CD28PD-1CD28PD 1CD28PD-1:CD28 switch receptorchimeric PD1-Dap10-CD3zeta